Bacteria-based drug developer BiomX raises $24 million Series A

 

The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., and Takeda Ventures, Inc. with participation from other international venture firms. BiomX comes from the FutuRx incubator which is partly funded by the Israel Innovation Authority. The company seeks to develop new therapies for unmet medical needs using its understanding of the human microbiome, the bacteria that reside in and on the human body. The study of microbiome is a developing new pharmaceutical and nutritional field.

The company’s pipeline of drugs consists of products for the treatment of acne, inflammatory bowel disease (IBD), cancer, and therapeutics that modulate the microbiome for improved performance of immuno-oncology drugs.

To read more, click here.

Author: Ethan Goldspiel

Comments are disabled.